Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register

INTRODUCTION: Since March 2011, the microbial collagenase of Clostridium histolyticum (Xiapex®, Swedish Orphan Biovitrum AB, Stockholm, Sweden) has become available in the European Union for treatment of Dupuytren’s disease. The purpose of this study was to evaluate potential safety risks of Xiapex®...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohit, Arora, Peter, Angermann, Paul, Aspalter, Anja, Binter, Christian, Deml, Renate, Danninger, Stefan, Gärner, Dietmar, Hager, Johannes, Jeschke, Peter, Kaiser, Marco, Keller, Martin, Leixnering, Maximilian, Neuwirth, Christoph, Pezzei, Gernot, Schmidle, Gerald, Schmölzer, Tobias, Steirer, Matthias, Wlk, Armin, Zadra, Markus, Gabl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Handsurgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689902/
https://www.ncbi.nlm.nih.gov/pubmed/31317303
http://dx.doi.org/10.1007/s00402-019-03226-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689902/
https://www.ncbi.nlm.nih.gov/pubmed/31317303
http://dx.doi.org/10.1007/s00402-019-03226-3

Ejemplares similares